Results indicated that mean AUASI scores decreased from 14.7 to 11.7 in placebo patients and 14.4 to 12.2 in saw palmetto patients with mean averages favoring the placebo treatment. When comparing secondary outcomes (nocturia, post-void residual volume, prostate-specific antigen, sexual function, and prostatitis symptoms), there were again no effective results seen in patients with saw palmetto treatment. This evidence concerns the gene KLK3 and medical procedure.